Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000711458 | SCV000841826 | uncertain significance | not provided | 2017-11-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000797096 | SCV000936636 | likely benign | Duchenne muscular dystrophy | 2024-11-24 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000711458 | SCV004234337 | uncertain significance | not provided | 2023-02-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026804 | SCV005021726 | uncertain significance | Cardiovascular phenotype | 2024-03-12 | criteria provided, single submitter | clinical testing | The p.R1470H variant (also known as c.4409G>A), located in coding exon 32 of the DMD gene, results from a G to A substitution at nucleotide position 4409. The arginine at codon 1470 is replaced by histidine, an amino acid with highly similar properties. Based on data from gnomAD, the A allele has an overall frequency of <0.01% (1/182821) total alleles studied, with 1 hemizygote(s) observed. The highest observed frequency was <0.01% (1/81465) of European (non-Finnish) alleles. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001825418 | SCV002085326 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2018-09-20 | no assertion criteria provided | clinical testing |